A phase I and pharmacokinetic (PK) study of weekly docetaxel (D), cisplatin (P), and daily capecitabine (C) (DPC) in patients with advanced solid tumors.

被引：0
|
作者：
Fakih, MG
Zamboni, WC
Ramnath, N
Javie, MM
Schwarz, JK
French, RA
Regal, LL
Gorenflo, RK
Creaven, PJ
机构：
[1] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[2] Hillman Canc Res Ctr, Pittsburgh, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2092
引用
收藏
页码：150S / 150S
页数：1
相关论文
共 50 条
  • [1] A phase I and pharmacokinetic (PK) study of weekly docetaxel (D), cisplatin (P), and daily capecitabine (C) (DPC) in patients with advanced solid tumors.
    Reddy, NM
    Zamboni, WC
    Creaven, PJ
    Ramnath, N
    Javle, MM
    Strychor, S
    Repinski, TVW
    Zamboni, BA
    Schwarz, JK
    French, RA
    Fakih, MG
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 146S - 146S
  • [2] Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors
    Fakih, MG
    Creaven, PJ
    Ramnath, N
    Trump, D
    Javle, M
    Strychor, S
    Repinski, TV
    Zamboni, BA
    Schwarz, JK
    French, RA
    Zamboni, WC
    CLINICAL CANCER RESEARCH, 2005, 11 (16) : 5942 - 5949
  • [3] Phase I pharmacokinetic (PK) study of daily imatinib in combination with docetaxel for patients with advanced solid tumors.
    Chatta, GS
    Fakih, M
    Ramalingam, S
    Belani, CP
    Ramanathan, RK
    Zamboni, N
    Friedland, D
    Lis, D
    Tutchko, S
    Egorin, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 138S - 138S
  • [4] A phase I clinical and pharmacokinetic (PK) study of paclitaxel (P) and docetaxel (D) in patients (PTS) with solid tumors.
    Izquierdo, MA
    Pontón, JL
    García, M
    Navarro, M
    Mesia, R
    Cardenal, F
    Gil, M
    Germá, JR
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S84 - S84
  • [5] A phase I study of lenalidomide and weekly docetaxel in patients with advanced solid tumors.
    Papadopoulos, K
    Mendelson, D
    Preston, GG
    Lopez, AM
    Ricart, AD
    Schwartz, G
    Needle, MN
    Gordon, MS
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9116S - 9116S
  • [6] Phase I study of weekly docetaxel and topotecan in the treatment of advanced solid tumors.
    Tan, BR
    Read, W
    Bergeron, K
    Fracasso, PM
    Govindan, R
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 702S - 702S
  • [7] A phase I safety and pharmacokinetic (PK) study of navitoclax (N) in combination with docetaxel (D) in patients (pts) with solid tumors.
    Puglisi, M.
    van Doorn, L.
    Blanco-Codesido, M.
    De Jonge, M. J.
    Moran, K.
    Yang, J.
    Busman, T.
    Franklin, C.
    Mabry, M.
    Krivoshik, A.
    Humerickhouse, R.
    Molife, L. R.
    Eskens, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] A phase I study of aflibercept, pemetrexed (P), and cisplatin (C) in patients with advanced solid tumors.
    Townsley, C. A.
    Siu, L. L.
    Pedro-Salcedo, M. San
    Liu, L.
    Wakelee, H. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Phase I trial of weekly irinotecan plus docetaxel in patients with advanced solid tumors.
    Font, A
    Sánchez, JM
    Guillot, M
    Abad, A
    Taron, M
    Margelí, M
    Barnadas, A
    Rosell, R
    ANNALS OF ONCOLOGY, 2000, 11 : 141 - 141
  • [10] Phase I and translational study of capecitabine, cisplatin, and irinotecan in patients with solid tumors.
    Verschraegen, CF
    Lee, FC
    Rabinowitz, I
    Mangalik, A
    Jennings, C
    Maestas, A
    Shen, Z
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 155S - 155S
12345